vorinostat + bevacizumab + carboplatin + paclitaxel

This is a four-drug combination regimen consisting of vorinostat, bevacizumab, carboplatin, and paclitaxel. - **Vorinostat** is a small molecule histone deacetylase (HDAC) inhibitor that modulates gene expression by altering chromatin structure, leading to cell cycle arrest and apoptosis in cancer cells. - **Bevacizumab** is a monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis required for tumor growth. - **Carboplatin** is a platinum-based chemotherapeutic agent that causes DNA crosslinking and apoptosis in rapidly dividing cells. - **Paclitaxel** is a microtubule-stabilizing agent that disrupts mitosis by preventing microtubule depolymerization, leading to cell death. This combination has been investigated primarily for the treatment of advanced solid tumors such as ovarian cancer and non-small cell lung cancer. The rationale for combining these agents lies in their complementary mechanisms—targeting epigenetic regulation (vorinostat), tumor vasculature (bevacizumab), DNA integrity (carboplatin), and mitotic spindle function (paclitaxel)—to maximize antitumor efficacy.

Brand names

ZolinzaAvastinParaplatinTaxol

Other names

suberoylanilide hydroxamic acid